Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its second quarter 2025 results.
Read Article
New GLP-1 analysis reveals that by addressing real-world barriers to persistence, Omada’s companion program can help sustain GLP-1 use, delivering on clinical trials' promises
Read Article
Medication persistence, or remaining on a medication as prescribed, is crucial for meaningful obesity management outcomes.
Read Resource
Error - something went wrong!
Become an Omada Insider, subscribe to our monthly newsletter
Thank you!
Omada Health, the virtual between-visit healthcare provider, today announced the pricing of its initial public offering of 7,900,000 shares of its common stock, at a public offering price of $19.00 pe
Read Article
Omada Health announces its initial public offering, offering 7.9 million shares at $18–$20 each, and plans to list on Nasdaq under the ticker symbol “OMDA.”
Read Article
On May 20, 2025, Omada Horizon Day showcased how our AI-powered innovations are transforming member relationships with food. Watch the recording of our Spring 2025 product innovation unveiling!
Watch Video
Why GLP-1s are not a silver bullet for obesity, the role of behavior change support teams and how they complement obesity medicine specialists, and how providers can achieve optimal outcomes.
Read Article
This edition covers the imminent expansion of GLP-1s on a worldwide scale, the global burden and prevalence of obesity and chronic diseases, and the clinical and economic realities of GLP-1 expansion.
Read Article
Self-efficacy is key for long-term GLP-1 weight loss success. Find out how Omada’s Enhanced GLP-1 Care Track helps members achieve sustainable weight health.
Read Article
This analysis found that lifestyle-focused virtual health program to support cardiometabolic disease management may lead to meaningful reductions in high-cost acute care encounters.
Read Article
This analysis evaluated demographic & clinical characteristics of adults without diabetes who reported recent use of GLP-1s for weight loss while enrolled in a digital weight management program.
Read Article
As the GLP-1 conversation evolves, Omada Health is updating its industry FAQs to deliver timely data and insights for virtual care buyers.
Read Article
Should you trust healthcare AI? Learn about safe development and deployment practices, and the future of AI regulation in healthcare.
Read Article
Omada Health presented three posters at the Society of Behavioral Medicine's Annual Meeting. New data demonstrates behavioral, mental, and physical health benefits of Omada's cardiometabolic programs.
Read Article
This analysis found that providing Omada members the opportunity to make a guided decision about curriculum theme resulted in greater engagement compared to receiving content in a standardized order.
Read Article
Become an Omada Insider, subscribe to our monthly newsletter.
Sign me upOmada’s Clinical Advisory Board demonstrates its commitment to rigorous clinical evaluation and helps underscore the impact of its behavior change programs
Read Article
This analysis showed that across diverse sociodemographic populations, Omada cardiometabolic members experienced improvements in depression and anxiety symptoms.
Read Article
This analysis found that providing Omada members the opportunity to make a guided decision about curriculum theme resulted in greater engagement compared to receiving content in a standardized order
Read Article
Case Study: Learn how Omada Health and Sentara Health plans collaborate to advance health equity in government programs.
Read Resource
In a survey of over 2,000 doctors, a majority believed GLP-1s need to be paired with changes in diet and exercise to be effective in driving healthy weight loss.
Read Article
Loading More...
